Infection Linked to Dangerous Blood Clots in Veins and Lungs
Michigan Medicine - University of MichiganOlder adults at much greater risk for being hospitalized for a blood clot within three months of getting an infection.
Older adults at much greater risk for being hospitalized for a blood clot within three months of getting an infection.
A natural enzyme derived from human blood plasma showed potential in significantly reducing the effects of graft-vs.-host disease, a common and deadly side effect of lifesaving bone marrow transplants.
A Rush University Medical Center led international research team has announced that a treatment to prevent bleeding episodes in children with hemophilia A also is effective for adolescents and adults.
Highlights • Correcting anemia in kidney transplant recipients slows the progression of kidney failure and improves the function of transplanted kidneys. • Transplant patients with completely corrected anemia experience a significant improvement in quality of life. • Anemia is a common complication of kidney transplantation, with a prevalence of 25% to 40% after the first year.
Symptoms improved significantly in adults with the bleeding disorder hemophilia B following a single treatment with gene therapy developed by researchers at St. Jude Children’s Research Hospital in Memphis and demonstrated to be safe in a clinical trial conducted at the University College London (UCL) in the U.K.
Researchers at the Salk Institute for Biological Studies have developed a way to use patients' own cells to potentially cure sickle cell disease and many other disorders caused by mutations in a gene that helps produce blood hemoglobin.
For the first time, researchers have combined gene therapy and stem cell transplantation to successfully reverse the severe, crippling bleeding disorder hemophilia A in large animals, opening the door to the development of new therapies for human patients.
Few options are availabe to prevent the painful episodes of sickle cell disease. But a University of Michigan Health System study reveals a protein trigger that could lead to a new treatment for sickle cell patients.
A University of Michigan Health System-led team of researchers has found a biomarker they believe can help rapidly identify one of the most serious complications in cancer patients after a bone marrow transplant.
Using a patient’s own stem cells, researchers at Johns Hopkins have corrected the genetic alteration that causes sickle cell disease (SCD), a painful, disabling inherited blood disorder that affects mostly African-Americans. The corrected stem cells were coaxed into immature red blood cells in a test tube that then turned on a normal version of the gene.